See the DrugPatentWatch profile for histamine
What histamine biosynthesis claims are typically seen in US patent applications?
US patent applications that cover “histamine biosynthesis” usually claim one or more of these elements: (1) methods or engineered systems that produce histamine, (2) enzymes or genetic constructs that enable histamine formation, and (3) host cells or production platforms used for manufacturing histamine or histamine-containing products. Claims often focus on specific biochemical steps such as converting histidine to histamine using histidine decarboxylase (HDC), or on upstream/downstream pathways that change histamine levels.
Because “histamine biosynthesis” can include multiple pathway contexts (dietary/commensal production, microbial production, engineered industrial biosynthesis, and therapeutic modulation of histamine formation), the claim language can differ widely even when the overall goal is “making histamine.”
What exact claim terms should you search for in US applications?
Common US patent claim language and technical keywords related to histamine biosynthesis include:
- “histidine decarboxylase” (HDC), “HDC activity,” or “decarboxylation of histidine to histamine”
- “histamine production,” “histamine biosynthesis,” or “histidine decarboxylase pathway”
- “engineered” or “recombinant” cells expressing HDC or pathway enzymes
- “host cell,” “microorganism,” “fermentation,” or “biocatalyst” used to generate histamine
- “method of producing histamine” with process steps (culturing, inducing expression, collecting product)
- “modulating” histamine biosynthesis (e.g., increasing or decreasing histamine generation via pathway control)
If your goal is to identify “histamine biosynthesis claims” in particular, you generally get the most relevant hits by searching both the biological term (HDC/histidine decarboxylation) and the claim framing (“method of producing,” “engineered cell,” “host cell,” “composition comprising,” etc.).
Are there US applications that claim inhibitors or pathway modulation instead of histamine production?
Yes. Some US applications do not claim biosynthesis as “making histamine,” but instead claim reducing histamine formation by inhibiting HDC or altering histamine-producing pathways. In those cases, you’ll see claims framed around:
- “inhibiting histidine decarboxylase”
- “reducing histamine biosynthesis”
- “treating” conditions associated with histamine release or elevated histamine levels
This matters because patent searchers sometimes assume “biosynthesis” always means production; in patent language, it can also mean “the pathway producing histamine,” even when the invention aims to block it.
How do you find the actual US claims quickly (not just abstracts)?
To extract “claims” from US applications, you generally need to open the application record and read the “Claims” section directly. Search strategies that help:
- Use the CPC (classification) and full-text search around “histidine decarboxylase” and “histamine”
- Filter to US application publications (US20xx…A1) and then open the document to read the claim set
- Look for independent claims that define the core inventive concept (the first claims usually do)
If you share the specific context you mean (industrial production vs therapeutic modulation vs microbial/food-related production), I can help narrow the most likely claim structures and keywords to target.
Do you mean claims in a specific patent, or just “types of claims” across applications?
Your wording could mean either:
1) “What do US patent applications claim when they cover histamine biosynthesis?” (claim patterns/keywords), or
2) “What claims does [specific patent/application] make about histamine biosynthesis?” (a document-specific extraction)
If you paste a US publication number (for example, US20xx…A1), an assignee name, or a link to the application, I can summarize the specific histamine-biosynthesis-related claims from that document.